Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, and tolerability of HLA-A*2402
restricted epitope peptide VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination
with gemcitabine
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fukushima Medical University
Collaborator:
Human Genome Center, Institute of Medical Science, University of Tokyo